Novo Nordisk has confirmed TGA approval of SAXENDA (liraglutide) as the first once-daily glucagon-like peptide-1 receptor agonist for chronic weight management. …
Latest Video
New Stories
-
Companies welcome November PBAC outcomes
December 23, 2024 - - Latest News -
The 'Dispatched' Podcast - 'This draws a line through everything and it's not good'
December 22, 2024 - - Podcast -
'Found irregularities and anomalies in the instruments of delegation from the minister'
December 20, 2024 - - Latest News -
FDA approves Mesoblast's cell therapy to treat steroid-refractory acute graft-versus-host disease
December 19, 2024 - - Australian Biotech -
Wholesalers secure five-year agreement with the Government
December 19, 2024 - - Latest News -
When the Government funds a health technology, the community makes certain assumptions
December 19, 2024 - - Latest News -
If this decision to undermine the TGA reflects a policy decision, be transparent about it
December 18, 2024 - - Latest News